Zhe Jiang Hua Hai Pharmaceuticalco.Ltd(600521) 10 announced that the company recently received a notice from the U.S. Food and Drug Administration (FDA) that the brief application for a new drug of nabilol tablets declared by the company to the U.S. FDA has been approved.
The announcement shows that nabilol tablets are mainly used to treat hypertension. Up to now, the company has invested about 10.73 million yuan in the research and development cost of nabilol tablets.
The approval of the Anda document number of nabilol tablets indicates that Zhe Jiang Hua Hai Pharmaceuticalco.Ltd(600521) has the qualification to sell the product in the U.S. market, which is conducive to the company's continuous expansion of U.S. market sales, strengthening product supply chain, enriching product echelons, improving the market competitiveness of the company's products, and will have a positive impact on the company's business performance.
